← All trials
NCT00827138
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2009
- Primary completion
- Jan 1, 2013
- Completion date
- Jan 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Deciphera Pharmaceuticals LLCLead sponsor
- University of ChicagoOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- Medical College of WisconsinOverall official - principal investigator
- University of South FloridaOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- Johns Hopkins UniversityOverall official - principal investigator
- Tufts UniversityOverall official - principal investigator
- University of MichiganOverall official - principal investigator
- University of KansasOverall official - principal investigator
- City of Hope National Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.